Sodium-Glucose Transporter 2 Inhibitor

SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.

PHILADELPHIA — In patients with HF with reduced ejection fraction, the four pillars of optimal medical therapy should be started as soon as possible, a speaker said here.

In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”

SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association.

Testing the effectiveness of an innovative, clinic-level educational intervention to improve management of people with type 2 diabetes and CVD.

Healio and Cardiology Today have compiled the top cardiology headlines of April 2023.

NEW ORLEANS — Implementing a coordinated care intervention in U.S. cardiology clinics led to a fourfold increase in the prescription of three groups of guideline-recommended therapies in adults with type 2 diabetes and atherosclerotic CVD.

NEW ORLEANS — Implementing a coordinated care intervention in U.S. cardiology clinics led to a fourfold increase in the prescription of three groups of guideline-recommended therapies in adults with type 2 diabetes and atherosclerotic CVD.

Defining eligibility criteria for initiation of guideline-directed medical therapy and new HF agents.

Findings from a meta-regression analysis indicated that the beneficial effects of SGLT2 inhibition on CV death and HF hospitalization in patients with diabetes may be related to body weight.